Merck & Co. Inc. MRK announced its intention to acquire privately held biotech company Afferent Pharmaceuticals in a deal which could see the company paying up to $1.25 billion. Deal to Add Chronic ...
SAN MATEO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals, a leader in the development of small molecule compounds targeting P2X3 for the treatment of respiratory and urologic disorders, as well as ...
Afferent Pharmaceuticals today announced publication of results from a Phase 2 clinical trial demonstrating that the company's novel drug candidate, AF-219, reduced daytime cough frequency by 75% ...
The dorsal root ganglia (DRG) project spinal afferent axons to the stomach. However, the distribution and morphology of spinal afferent axons in the stomach have not been well characterized. In this ...
Afferent’s compounds selectively block ATP activation of P2X3 channels, reducing a range of sensory signs and symptoms. P2X3 receptor-mediated sensitization has also been implicated in inflammatory, ...
Merck & Co has agreed to buy Afferent Pharmaceuticals, and its lead respiratory drug, in a deal worth up to $1.25 billion. The acquisition comes at a time when Merck’s revenues are beginning to ...
Back in February, Afferent Pharmaceuticals pronounced itself satisfied with the outcome for a mid-stage study of its lead drug, AF-219, being developed for a range of conditions including pain, ...
Afferent Also Appoints Kathleen Sereda Glaub to the Company's Board of Directors SAN MATEO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals today announced that Michael M. Kitt, M.D., has been named ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results